Trial ID or NCT#

NCT01928030

Status

NOT RECRUITING

Purpose

This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in patients with lymphedema.

Official Title

Pilot Phase 1-2 Investigational Study to Assess the Efficacy and Safety of Recombinant Hyaluronidase (rHUPH20) in the Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Stanley G. Rockson, MD
Cardiologist
Allan and Tina Neill Professor of Lymphatic Research and Medicine
Mark Pegram, MD
Medical oncologist, Breast specialist
Susy Yuan-Huey Hung Professor

Contact us to find out if this trial is right for you.

CONTACT

Les Roche
(650) 723-1396